Anavex Life Sciences Corp. (AVXL)
AVXL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.48
-1.99% on the day
Market cap
$137.2M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AVXL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001314052 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NEVADA |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2025-07-25 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-08-28 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-28 |
| Latest current report FORM 8-K | 8-K | 2026-09-28 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-09-15 |
Source: SEC EDGAR submissions feed, 630 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics Inc. | $0.5638 | -3.64% | $137.3M |
| MOLN | Molecular Partners AG | $3.67 | -3.17% | $137.7M |
| VYGR | Voyager Therapeutics Inc. | $2.15 | -5.29% | $132.5M |
| ABOS | Acumen Pharmaceuticals Inc. | $1.81 | -10.15% | $131.3M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $1.20 | +1.70% | $144.8M |
| CMPX | Compass Therapeutics Inc. | $0.8570 | -8.59% | $154.3M |
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| TNYA | Tenaya Therapeutics Inc. | $0.5210 | -7.87% | $116.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier